NEW YORK, Sept. 20 – Hybrigen and Bionomics Limited have signed a letter of intent to negotiate a partnership to study a pair of genes linked to breast cancer, the companies said on Thursday.
The target-discovery program will study the genes, TSG18 and BNO1, using genetic data identified and patented by Adelaide, Australia-based Bionomics, the firms said in a statement. For its part, Hybrigen, based in Dallas, will use its own proprietary proteomic technologies to discover drug targets that interact with those genes.
Both firms will share any drug targets developed from their collaboration.
TSG18 is currently being studied as a suppressor gene in certain breast cancers, while BNO1 has been shown to trigger apoptosis in certain breast cancer cells, Hybrigen and Bionomics said.